Latest News
Jason Meyer, PhD, is a BrightFocus Foundation success story and a pioneer in the effort to regenerate eye tissue that is damaged by glaucoma.
Findings are the first to show a statistically significant decrease in cognitive decline by an anti-amyloid drug.
New BrightFocus-funded research explores how a protein called tau, critical to Alzheimer’s, turns from normal to a diseased state. This discovery presents a new target to potentially prevent or treat Alzheimer's disease.
Eye-brain research is revealing that the APOE4 mutation has a much different impact in glaucoma than in Alzheimer’s, a discovery that may lead to a new glaucoma treatment.
In this issue:
- New Ways to Diagnose and Monitor Glaucoma
- President's Corner
- Gene for Repairing Retinal Cells Identified
- And More!
A team including two BrightFocus grantees has successfully transplanted a patch of retinal tissue into a patient with geographic atrophy. This experimental therapy was part of an NIH clinical trial and marks the first time in the U.S. that stem cells derived from a patient’s own tissue have been used to replace eye cells.
A new oral pill for geographic atrophy is being tested in an early-stage clinical trial.
Donald Weaver’s $1 million BrightFocus Centennial grant helped lead to his new exploration of Alzheimer’s roots, which he and colleagues have proposed may lie with an out-of-control autoimmune reaction.
The impact factor of Molecular Neurodegeneration, the official scientific journal of BrightFocus Foundation, has risen to 18.879, according to its publisher, up from 14.195 a year ago.
In this issue:
- President's Corner
- Researcher Spotlight: Laura Cox, PhD
- Study Explains Why Impact of Genetic Risk Factor Varies by Ancestry
- And more!
